logo-loader
viewGold Road Resources Ltd

Gold Road Resources upgrades gold potential at Gruyere Joint Venture

The new JORC resource totals 327,300 ounces of gold grading 1.55 g/t gold.

WA-Map-7---757.jpg
Gold Road started a $30 million exploration program in the March quarter

Gold Road Resources (ASX:GOR) has completed a major upgrade to the Attila Open Pit resource at the Gruyere Joint Venture in Western Australia.

The Gruyere Joint Venture is a 50:50 joint venture with Gold Fields (JSE:GFI), situated 30 kilometres west of the Gruyere Gold Project.

The new JORC resource totals 6,570,900 tonnes at 1.55 g/t gold for 327,300 ounces of gold.

This represents an addition of 103,200 ounces (+46%) compared to the 2015 resource, with 91% of the resource being classified in the measured or indicated categories.

The updated resource includes new information derived from the 2016 diamond and reverse circulation drilling programs which contributed to the refinement of the geological understanding at Attila.

Importantly, the update reflects the work done by the exploration team in applying smart geology and efficient drilling to extend this historic resource.

The joint venture now has more than 14 kilometres of known mineralisation along the Attila-Alaric Trend.

The March 2017 quarter saw the start of Gold Road’s $30 million 2017 Yamarna greenfields exploration program, which will include:

- $15 million committed to regional exploration on the North Yamarna tenements; 
- $11 million committed (Gold Road: $5.5 million) to drilling within the Gruyere JV; and  
- $3.3 million (Gold Road: $1.65 million) committed on the South Yamarna JV.

As at 31 March 2017, the company had cash and other current assets of $415.9 million.

Quick facts: Gold Road Resources Ltd

Price: 1.45 AUD

ASX:GOR
Market: ASX
Market Cap: $1.27 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: TRACON Pharmaceuticals reveals its low-cost drug development...

TRACON Pharmaceuticals (NASDAQ:TCON) CEO Charles Theuer tells Proactive the biotechnology company ended 2019 with cash, cash equivalents and short-term investments of $16.4 million. Theuer explains despite engaging in five different clinical trials, three of the five company's clinical trials...

8 hours, 56 minutes ago

2 min read